Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne Mortimer

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Research Square|January 16, 2026
GLP-1 Targeting Agents Impair Chemoimmunotherapy Effectiveness in Triple-Negative Breast CancerJoshua Gruber, Bethania Soares Dos Santos, Maycon Marção, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 12, 2023
Predicting All-Cause Mortality in Women With and Without Breast Cancer Using the Schonberg Index: A Women's Health Initiative StudyRebecca A Nelson, Enrique Soto-Perez-de-Celis, Rowan T Chlebowski, et al.
Breast Cancer Research and Treatment|January 10, 2022
The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women's Health InitiativeSidney M Donzella, Kimberly E Lind, Meghan B Skiba, et al.
Cancers|September 9, 2022
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast CancerXuan Ge, Susan E Yost, Jin Sun Lee, et al.
Breast Cancer Research : BCR|November 10, 2019
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancerJin Sun Lee, Susan E Yost, Suzette Blanchard, et al.
Gynecologic Oncology|January 23, 2024
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancerMihaela C Cristea, Daphne Stewart, Timothy Synold, et al.
Journal of Clinical Medicine|May 28, 2020
Strategies to Improve Participation of Older Adults in Cancer ResearchJennifer Liu, Eutiquio Gutierrez, Abhay Tiwari, et al.
JCO Precision Oncology|September 14, 2020
Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing ReportIlana B Solomon, Sarah McGraw, Jenny Shen, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 8, 2016
Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancersNoriko Kanaya, George Somlo, Jun Wu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 4, 2021
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancerYuan Yuan, Jin Sun Lee, Susan E Yost, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Research Square|January 16, 2026
GLP-1 Targeting Agents Impair Chemoimmunotherapy Effectiveness in Triple-Negative Breast CancerJoshua Gruber, Bethania Soares Dos Santos, Maycon Marção, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 12, 2023
Predicting All-Cause Mortality in Women With and Without Breast Cancer Using the Schonberg Index: A Women's Health Initiative StudyRebecca A Nelson, Enrique Soto-Perez-de-Celis, Rowan T Chlebowski, et al.
Breast Cancer Research and Treatment|January 10, 2022
The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women's Health InitiativeSidney M Donzella, Kimberly E Lind, Meghan B Skiba, et al.
Cancers|September 9, 2022
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast CancerXuan Ge, Susan E Yost, Jin Sun Lee, et al.
Breast Cancer Research : BCR|November 10, 2019
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancerJin Sun Lee, Susan E Yost, Suzette Blanchard, et al.
Gynecologic Oncology|January 23, 2024
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancerMihaela C Cristea, Daphne Stewart, Timothy Synold, et al.
Journal of Clinical Medicine|May 28, 2020
Strategies to Improve Participation of Older Adults in Cancer ResearchJennifer Liu, Eutiquio Gutierrez, Abhay Tiwari, et al.
JCO Precision Oncology|September 14, 2020
Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing ReportIlana B Solomon, Sarah McGraw, Jenny Shen, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 8, 2016
Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancersNoriko Kanaya, George Somlo, Jun Wu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 4, 2021
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancerYuan Yuan, Jin Sun Lee, Susan E Yost, et al.
Pageof 11